Primary ovarian lymphoma as the initial manifestation is rare. A 27-year-old woman presented to our hospital with the symptoms of lower abdominal fullness and pollakisuria. CT scan and MRI revealed bilateral ovarian tumors, which showed heterogeneous masses.18F-FDG PET revealed strong uptake by the abdominal masses, and the maximum standardized uptake value (SUVmax) was 12.5. Abnormal uptake was not shown by other regions. An exploratory laparotomy was performed. Histological findings revealed diffuse large B-cell lymphoma. The clinical stage was IV according to the Ann Arbor system. International prognostic index (IPI) was 3 (high-intermediate risk). Chemotherapy was administered consisting of three courses of an R-CHOP regimen, and18F-FDG PET and CT scan revealed no signs of involvement 3 months after initiation of the chemotherapy.18F-FDG PET was a useful method for staging and assessment of the therapeutic response in primary ovarian lymphoma.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Chorlton I, Noms HJ, King FM. Malignant reticuloendothelial disease involving the ovary as a primary manifestation: a series of 19 lymphomas and 1 granulocystic sarcoma.Cancer 1974; 34:397–407.
Linden MD, Tubbs RR, Fishleder AJ, Hart WR. Immunotypic and genotype characterization of non-Hodgkin’s lymphoma of the ovary.Am J Clin Pathol 1988; 90:156–162.
Skodras G, Fieids V, Kragel PJ. Ovarian lymphoma and serous carcinoma of low malignant potential arising in the same ovary: a case report with literature review of 14 primary ovarian lymphomas.Arch Pathol Lab Med 1994; 118:647–650.
Dimopoulos MA, Daliani D, Pugh W, Gershenson D, Cabanillas F, Sarris AH. Primary ovarian non-Hodgkin’s lymphoma: outcome after treatment with combination chemotherapy.Gynecol Oncol 1997; 64:446–450.
Nakamura S, Kato M, Ichimura K, Yatabe Y, Kagami Y, Suzuki R, et al. Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases.Int J Hematol 2001; 73:108–114.
Vang R, Medeiros LJ, Fuller GN, Sarris AH, Deavers M. Non-Hodgkin’s lymphoma involving the gynecologic tract: a review of 88 cases.Adv Anat Pathol 2001; 8:200–217.
Roth H, Daum R, Benz K, Schafer K. Rare ovarian tumors in childhood.Eur J Pediatr Surg 1991; 1:210–215.
Osborne BM, Robboy ST. Lymphomas or leukemia presenting as ovarian tumors, an analysis of 42 cases.Cancer 1983; 52:1933–1943.
Ferrozzi F, Tognini G, Bova D, Zuccoli G. Non-Hodgkin lymphomas of the ovaries: MR findings.J Comput Assist Tomogr 2000; 24:416–420.
Weingertner AS, Hamid D, Roedlich MN, Baldauf JJ. Non-Hodgkin malignant lymphoma revealed by an ovarian tumor: case report and review of the literature.Gynecol Oncol 2004; 95:750–754.
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography withl8F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma.Ann Oncol 2002; 13:1356–1362.
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, et al. Persistent tumor18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma.Haematologica 2000; 85:613–618.
Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Soderstrom KO, et al. Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.Blood 1995; 86:3522–3527.
Yamane T, Daimaru O, Ito S, Yoshiya K, Nagata T, Uchida H. Decreased18F-FDG uptake 1 day after initiation of chemotherapy for malignant lymphomas.J Nucl Med 2004; 45:1838–1842.
About this article
Cite this article
Komoto, D., Nishiyama, Y., Yamamoto, Y. et al. A case of non-Hodgkin’s lymphoma of the ovary: Usefulness of18F-FDG PET for staging and assessment of the therapeutic response. Ann Nucl Med 20, 157–160 (2006). https://doi.org/10.1007/BF02985629